2 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
Follow Shunda Du: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC Lenalidomide, Targeted Therapy, Immune Checkpoint Inhibitors - Hepatocellular Carcinoma (HCC) | Phase 2 | Recruiting | Shunda Du | 32 | 2026-08-12 | 2026-09-21 |
| Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma Irreversible Electroporation, Lenvatinib, Sintilimab - Hepatocellular Carcinoma (HCC) | Phase 2 | Recruiting | Shunda Du | 30 | 2025-04-01 | 2026-09-21 |
Electroporation (1) · Immune Checkpoint Inhibitors (1) · Lenalidomide (1) · lenvatinib (1) · sintilimab (1)
China (2)